Verily and GlaxoSmithKline have partnered to form Galvani Bioelectronics, a new company which will focus on the research, development, and commercialization of bioelectronics. One of the first projects will be to develop a precision device that can fix type 2 diabetes.

Verily, formerly known as Google Life Sciences, is partnering with GlaxoSmithKline (GSK) to develop bioelectronic medicines that can “harness electrical signals in the body to treat chronic disease.”

The collaboration marries GSK’s pharmaceutical expertise with Verily’s prowess in developing tiny low power electronics. The unification will result in a new company called Galvani Bioelectronics, after Italian scientist Luigi Aloisio Galvani who was an early pioneer of bioelectricity.

When we look at the huge tech and industrial revolution that is just on the verge of happening due to QC and Medical technologies; synthetic diamonds will be a central piece of this story. I hope Intel, Nvidia, HP, Xerox, Apple, etc. all are assessing how they can either produce or partner with producers of synthetic diamonds. Printer companies could be big players in the mass production story of Synthetic Diamonds; and partnerships between Intel and HP or Intel and Xerox could prove to be fruitful.

COULD synthetic diamonds be key to developing the advanced electronics of tomorrow? A company crowd-funding on Cambridge’s SyndicateRoom thinks so.

Evince is looking to raise £650,000 to develop a working prototype of its new semi-conductor, which it says has the potential to perform 100 times better than silicon.

The company’s patented system combines advanced semiconductor and vacuum microelectronics concepts to create its platform technology.